A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD)

Inclusion Criteria:

• Male/female patients, 18 years or older
• Moderate to severe plaque-type psoriasis, candidate for systemic therapy
• Diagnosis of NAFLD by either ultrasound at Screening or liver histology within 6months before Baseline
• BMI > 25 kg/ m 2
• ALT 1.2 to 3.0 × ULN
• MRI confirmed Liver fat ≥ 8% at Screening

Exclusion Criteria:

• Forms of psoriasis other than chronic plaque-type Psoriasis
• Drug induced psoriasis
• Pregnant or nursing (lactating) women
• Women of child bearing potential unless they are using effective methods ofcontraception
• Ongoing use of prohibited treatments
• Previous treatment with biological drug targeting IL-17 or the IL-17 receptor
• Past medical history record of infection with human immunodeficiency virus (HIV),hepatitis B or hepatitis C prior to Screening
• Unstable weight over the last 6 months prior to Screening.
• Type I diabetes, or uncontrolled diabetes (Type I or Type II) defined as HbAlc ≥ 10%at screening.
• Evidence of hepatic decompensation or severe liver impairment or cirrhosis
• History of liver transplantation or planned liver transplant or biliary diversion.
• Presence or history of other liver disease
• Current, or history of, significant alcohol consumption for a period of more than 3consecutive months within 1 year prior to screening
• Prior or planned bariatric surgery
• Inability or unwillingness to undergo MRI of the abdomen
• Past medical history record of infection with human immunodeficiency virus (HIV),hepatitis B or hepatitis C prior to Screening